News
Eton Pharmaceuticals submits NDA to the FDA for orphan drug dehydrated alcohol injection (DS-100).
Eton Pharmaceuticals, Inc announced the FDA has accepted for filing the company’s new drug application (NDA) for dehydrated alcohol injection (DS 100). The application has been assigned a Prescription Drug User Fee Act (PDUFA) date of May 27, 2021.
Eton’s application previously received orphan drug designation for the treatment of methanol poisoning and is expected to receive seven years of market exclusivity upon its approval. The U.S. market for dehydrated alcohol injection is estimated to be greater than $100 million annually and the drug is currently only supplied by a single manufacturer.
Condition: Methanol Poisoning
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins